Several listed companies in the A-shares market are reporting highly robust early-year performances, with the semiconductor and pharmaceutical sectors demonstrating strong prosperity and high-quality results.

According to Wind data statistics, as of March 23, a total of 8 listed companies in the A-share market have disclosed their performance forecasts for the first quarter, among which, except for one company that continues to report losses, the others all expect an increase, slight growth, or turnaround. At the same time, many A-share listed companies have intensively disclosed operational data for the past two months, voluntarily revealing their performance from the beginning of the year. After sorting through the information, it can be seen that the companies with performance growth are mostly concentrated in high-growth sectors such as pharmaceuticals and semiconductors.

Zhan Junhao, founder of Fujian Huace Brand Positioning Consulting, stated in an interview with the Securities Daily that many companies in the A-share market have disclosed operational data since the beginning of the year, indicating a strong overall start. “The high profitability realization of related companies shows that the industry’s recovery is not just a concept hype, but a resonance of real demand and capacity release, laying a solid foundation for the annual performance.”

Taking semiconductors as an example, Haiguang Information Technology Co., Ltd. (hereinafter referred to as “Haiguang Information”) is mainly engaged in the research and development of high-end processors, accelerators, and other computing chip products and systems. The company expects its operating revenue in the first quarter of 2026 to grow by 62.91% to 75.82% year-on-year; it expects to achieve a net profit attributable to the parent company’s owners of 620 million to 720 million yuan, an increase of 22.56% to 42.32% year-on-year.

Haiguang Information stated that the company continues to increase its investment in research and development, and its product competitiveness is continuously strengthening. The domestic high-end chip market demand continues to rise with the growing demand in the artificial intelligence industry. The company is promoting the expansion of its market presence for high-end processor products through continuous increases in R&D investment, continuous optimization of product performance, and enhancements in product iteration speed, resulting in significant growth in the company’s operating revenue and continuous growth in overall performance.

The operational data of related listed companies for the past two months also highlights the high prosperity of the semiconductor industry. On March 4, Shenzhen Baiwei Storage Technology Co., Ltd. (hereinafter referred to as “Baiwei Storage”) announced that, based on preliminary estimates, it expects to achieve operating revenue of 4 billion to 4.5 billion yuan from January to February 2026, a year-on-year increase of 340% to 395%; the net profit attributable to the parent company is expected to be 1.5 billion to 1.8 billion yuan, a year-on-year increase of 921.77% to 1086.13%.

Baiwei Storage stated that the semiconductor industry is entering a highly prosperous cycle in 2026, driven by AI computing power and domestic substitution, leading to continuous price increases for DRAM (Dynamic Random-Access Memory), creating a supply-demand imbalance from which the company significantly benefits. Furthermore, to enhance the competitiveness of the company’s products in the AI era, the company continues to increase investments in chip design, solutions, advanced packaging and testing equipment, and other areas.

Shanghai Weicai Semiconductor Technology Co., Ltd. primarily provides integrated circuit testing services. The announcement showed that from January to February, the company achieved consolidated operating revenue of 321 million yuan, a year-on-year increase of 79.15%. The significant improvement in operating performance during the reporting period is mainly attributed to the new expanded production capacity coming online, a substantial increase in high-end testing sales revenue, and a continuous rise in capacity utilization.

The announcement from Qiangyi Semiconductor (Suzhou) Co., Ltd. also indicated that, according to preliminary calculations by the finance department, it achieved consolidated operating revenue of 164 million yuan from January to February 2026, a year-on-year increase of 157.90%. The significant improvement in operating performance during this period is mainly due to the explosion of demand for AI computing power and the semiconductor industry’s prosperity cycle, with strong demand from leading downstream customers, resulting in rapid growth in the company’s high-end MEMS probe card business.

Zhan Junhao further believes that the core driving factor for the performance of the aforementioned semiconductor-related companies is the explosive demand for AI computing power, which drives an increase in both volume and price of upstream chips, combined with the end of inventory destocking in the industry and improved supply-demand dynamics. At the same time, the acceleration of domestic substitution is raising orders and market share for local enterprises, with the increase in both volume and price driving rapid performance growth.

In the pharmaceutical sector, benefiting from the implementation of medical insurance and commercialization expansion, innovative pharmaceutical companies are seeing steady performance growth. On March 7, Wanbangde Pharmaceutical Holdings Group Co., Ltd. (hereinafter referred to as “Wanbangde”) released its performance forecast for the first quarter of 2026. In the first quarter of this year, the company expects to achieve a net profit attributable to the parent company of 165 million yuan, a year-on-year increase of 985.4%.

Regarding the significant increase in performance, Wanbangde stated that during the reporting period, the company’s strategic transformation from generic drugs to innovative drugs has begun to show results, and business expansion has made positive progress, bringing new performance growth points. At the same time, the company has strengthened internal management and increased efforts to recover receivables, effectively accelerating the return of funds.

Shanghai Ailis Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Ailis”) is an innovative pharmaceutical company focusing on cancer treatment. The company expects to achieve revenue of 1.55 billion yuan in the first quarter of 2026, a year-on-year increase of 41.12%; and a net profit of 590 million yuan, a year-on-year increase of 43.73%.

Ailis stated that benefiting from the support and coverage of national medical insurance policies, the sales revenue of the company’s commercialized products and promotion service revenue continues to grow, driving the company’s operational performance to continue to rise.

Ding Zhenyu, a senior investment advisor at Jufeng Investment Consulting, told reporters: “The performance of the aforementioned listed companies at the start of the year is solid, fully validating the hard logic of AI computing power and domestic substitution. Overall, the performance growth of related listed companies is driven by their main businesses, with increases in both volume and price, rather than one-time gains, indicating sustainability and resulting from the upward industrial cycle and technological iteration resonance.”